Video

Goals of Treatment After Progression of HER2+ Metastatic Breast Cancer

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her goals of treatment after progression of disease.

Sara A. Hurvitz, M.D.: What side effects were important to you when you were deciding this [treatment upon progression for breast cancer]? What were your goals at that time? Because now, fast forward to when this happened, your sons were much older. Talk me through that a bit: where you were in life and how your goals and thoughts about treatment might have differed based on where you were when we first met.

Caitlin Flanagan: My treatment had always just been about being a mom and being alive for my kids. Sometimes, when they were in college, I would think, “What am I still doing here?” When they had elementary school graduation, I thought, “Yes! I made it to that.” Then came high school and college. After losing my hair twice, which I really hated, I really hoped I wouldn’t have to lose my hair. Some women don’t mind it. I think with younger women, there’s more of a range of how you can look in the world. I hated it. I hated how slowly it came back and in such a weird way. I didn’t want to be so sick, because I had been really sick. The first chemotherapy was so sickening. I guess I wanted everything I could get. I wanted to not lose my hair. I wanted to have some energy to still go about my day. I didn’t want to be drugged out. But I wanted one that could work. I am always such a big talker about not losing my hair again. Sara, if you told me, “You’re going to die in a month unless you give a Hail Mary pass to this one that’s going to cause you to lose your hair,” I bet I would reconsider very quickly.

And now, the women have those cold caps I see in the infusion [center] so they can preserve some of their hair. I would do that, I think.

Sara A. Hurvitz, M.D.: Yes, absolutely. The supportive measures we have for patients have vastly improved since you were initially diagnosed. The treatment options we have available have improved as well, with a number of these agents not leading to hair loss. That’s a good thing.

Transcript edited for clarity.


Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Picture of Dr. Pouneh Razavi
Image of a woman wearing a headband and glasses
Image of doctor.
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.